Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65

Publisher： Bentham Science Publishers

E-ISSN： 1875-5631|10|5|341-349

ISSN： 1566-5232

Source： Current Gene Therapy, Vol.10, Iss.5, 2010-10, pp. : 341-349

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immune Responses to AAV in Clinical Trials

By  

Current Gene Therapy, Vol. 7, Iss. 5, 2007-10 ,pp. : 316-324

Bentham Science Publishers

Access to resources Recommend Favorite

Immune Responses to AAV in Clinical Trials

By  

Current Gene Therapy, Vol. 11, Iss. 4, 2011-08 ,pp. : 321-330

Bentham Science Publishers

Access to resources Recommend Favorite

Interactions between AAV-2 and HSV-1: implications for hybrid vector design

By Glauser Daniel L   Fraefel Cornel  

Future Virology, Vol. 6, Iss. 4, 2011-04 ,pp. : 483-501

Future Medicine

Access to resources Recommend Favorite

Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD)

By  

Current Gene Therapy, Vol. 15, Iss. 4, 2015-01 ,pp. : 395-415

Bentham Science Publishers

Access to resources Recommend Favorite

Biologics Safety Preclinical, Clinical and Regulatory

By Hennig Renald  

Expert Opinion on Drug Safety, Vol. 2, Iss. 6, 2003-11 ,pp. : 609-611

Informa Healthcare

Access to resources Recommend Favorite